L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:742091 CAPLUS Full-text
DN 133:305587
TI Methods and compositions using bifunctional hsp-binding derivatives for degradation and/or inhibition of HER-family tyrosine kinases and treatment of cancer
IN Rosen, Neal; Kuduk, Scott D.; Danishefsky, Samuel J.; Zheng, Furzhong F.; Sepp-Lorenzino, Laura; Ouerfelli, Ouathek
PA Sloan-Kettering Institute for Cancer Research, USA
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061578	A1	20001019	WO 2000-US9512	20000407 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2370007	AA	20001019	CA 2000-2370007	20000407
	EP 1169319	A1	20020109	EP 2000-921985	20000407
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AU 769235	B2	20040122	AU 2000-42235	20000407
	US 2002045570	A1	20020418	US 2001-960665	20010921
PRAI	US 1999-128593P	P	19990409		
	WO 2000-US9512	W	20000407		

AB Bifunctional mols. comprising two hsp-binding moieties which bind to hsp90 in the pocket to which ansamycin antibiotics bind connected via a linker are effective for inducing the degradation and/or inhibition of HER-family tyrosine kinases. For example, a compound of two geldanamycin moieties joined by a four-carbon linker provides selective degradation of HER-family tyrosine kinases, without substantially affecting other kinases. These compds. can be used for treatment of HER-pos. cancers with reduced toxicity, since these compds. potently kill cancer cells but affect fewer proteins than geldanamycin. Compound preparation is described.

IT **80449-02-1**, Tyrosine kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HER-family; bifunctional hsp-binding derivative for degradation and/or inhibition of HER-family tyrosine kinase and cancer treatment)
RN 80449-02-1 CAPLUS
CN Kinase (phosphorylating), protein (tyrosine) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **30562-34-6**, Geldanamycin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(bifunctional hsp-binding derivative for degradation and/or inhibition of HER-family tyrosine kinase and cancer treatment)
RN 30562-34-6 CAPLUS
CN Geldanamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B

IT **71975-67-2P 280145-12-2P 280145-13-3P**
280145-14-4P 280145-15-5P 280145-16-6P
280145-17-7P 280145-18-8P 301643-24-3P
301643-25-4P 301643-26-5P 301643-27-6P
301643-28-7P 301643-29-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bifunctional hsp-binding derivative for degradation and/or inhibition of HER-family tyrosine kinase and cancer treatment)
RN 71975-67-2 CAPLUS
CN Geldanamycin, 17-(butylamino)-17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



RN 280145-12-2 CAPLUS
CN Geldanamycin, 17,17'-(1,4-butanediyldiimino)bis[17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 280145-13-3 CAPLUS
CN Geldanamycin, 17,17'-(1,7-heptanediyldiimino)bis[17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 280145-14-4 CAPLUS
CN Geldanamycin, 17,17'-(1,9-nonanediyldiimino)bis[17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 280145-15-5 CAPLUS
CN Geldanamycin, 17,17'-(1,11-undecanediyldiimino)bis[17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 280145-16-6 CAPLUS
CN Geldanamycin, 17-demethoxy-17-[[4-[[2-(hydroxymethyl)-4-methoxy-3,6-dioxo-1,4-cyclohexadien-1-yl]amino]butyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



RN 280145-17-7 CAPLUS

CN Geldanamycin, 17-[[4-[[4-amino-2-[(2R,4S,5R,6S,7E,9S,10S,11Z,13E)-9-[(aminocarbonyl)oxy]-5-hydroxy-4,10,15-trimethoxy-2,6,8,14-tetramethyl-15-oxo-7,11,13-pentadecatrienyl]-3,6-dioxo-1,4-cyclohexadien-1-yl]amino]butyl]amino]-17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C

RN 280145-18-8 CAPLUS

CN 2,4,8-Pentadecatrienoic acid, 15,15'-[1,4-butanediylbis[imino(5-amino-3,6-dioxo-1,4-cyclohexadiene-2,1-diyl)]]bis[7-[(aminocarbonyl)oxy]-11-hydroxy-6,12-dimethoxy-2,8,10,14-tetramethyl-, dimethyl ester, (2E,2'E,4Z,4'Z,6S,6'S,7S,7'S,8E,8'E,10S,10'S,11R,11'R,12S,12'S,14R,14'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 301643-24-3 CAPLUS
CN Geldanamycin, 17,17'-(1,12-dodecanediyldiimino)bis[17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 301643-25-4 CAPLUS
CN Geldanamycin, 17,17'-(1,5-pentanediyldiimino)bis[17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 301643-26-5 CAPLUS
CN Geldanamycin, 17,17'-(1,6-hexanediyldiimino)bis[17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 301643-27-6 CAPLUS
CN Geldanamycin, 17,17'-(1,8-octanediyldiimino)bis[17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 301643-28-7 CAPLUS
CN Geldanamycin, 17,17'-(1,10-decanediyldiimino)bis[17-demethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 301643-29-8 CAPLUS
CN Geldanamycin, 17,17'-(1,6-hexanediyldiimino)bis[17-demethoxy-, 15-methoxy-11-O-methyl deriv., (15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



IT **30562-34-6D**, Geldanamycin, linked derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)(bifunctional hsp-binding derivative for degradation and/or inhibition of HER-family tyrosine kinase and cancer treatment)
RN 30562-34-6 CAPLUS
CN Geldanamycin (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B

IT **137632-09-8**, HER-2 kinase **139691-76-2**, Raf-1 kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(bifunctional hsp-binding derivative for degradation and/or inhibition of HER-family tyrosine kinase and cancer treatment)
RN 137632-09-8 CAPLUS
CN Kinase (phosphorylating), protein p185neu (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 139691-76-2 CAPLUS
CN Kinase (phosphorylating), gene raf-1 protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **110-60-1**, 1,4-Butanediamine **124-09-4**, 1,6-Hexanediamine, reactions **373-44-4**, 1,8-Octanediamine **462-94-2**, 1,5-Pentanediamine **646-19-5**, 1,7-Heptanediamine **646-24-2**, 1,9-Nonanediamine **646-25-3**, 1,10-Decanediamine **822-08-2**, 1,11-Undecanediamine **2783-17-7**, 1,12-Dodecanediamine **70563-58-5**, Herbimycin A
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; bifunctional hsp-binding derivative for degradation and/or inhibition of HER-family tyrosine kinase and cancer treatment)
RN 110-60-1 CAPLUS
CN 1,4-Butanediamine (8CI, 9CI) (CA INDEX NAME)

$H_2N-(CH_2)_4-NH_2$

RN 124-09-4 CAPLUS
CN 1,6-Hexanediamine (7CI, 8CI, 9CI) (CA INDEX NAME)

$H_2N-(CH_2)_6-NH_2$

RN 373-44-4 CAPLUS
CN 1,8-Octanediamine (6CI, 8CI, 9CI) (CA INDEX NAME)

$H_2N-(CH_2)_8-NH_2$

RN 462-94-2 CAPLUS
CN 1,5-Pentanediamine (8CI, 9CI) (CA INDEX NAME)

$H_2N-(CH_2)_5-NH_2$

RN 646-19-5 CAPLUS
CN 1,7-Heptanediamine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

$H_2N-(CH_2)_7-NH_2$

RN 646-24-2 CAPLUS
CN 1,9-Nonanediamine (6CI, 8CI, 9CI) (CA INDEX NAME)

$H_2N-(CH_2)_9-NH_2$

RN 646-25-3 CAPLUS
CN 1,10-Decanediamine (6CI, 8CI, 9CI) (CA INDEX NAME)

$H_2N-(CH_2)_{10}-NH_2$

RN 822-08-2 CAPLUS
CN 1,11-Undecanediamine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

$H_2N-(CH_2)_{11}-NH_2$

RN 2783-17-7 CAPLUS
CN 1,12-Dodecanediamine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

$H_2N-(CH_2)_{12}-NH_2$

RN 70563-58-5 CAPLUS
CN Geldanamycin, 17-demethoxy-15-methoxy-11-O-methyl-, (15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT